Charles River Laboratories (CRL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $16.19B
Last updated: Nov 17, 2026 at 11:05 AM ET
Charles River Laboratories (CRL) Earnings: Report Dates and Results
Charles River Laboratories (CRL) is expected to report earnings on Feb 16, 2027. In the quarter ended Sep 30, 2026, Charles River Laboratories reported EPS of $3.09, above the $2.98 estimate. It beat the EPS estimate in each of the last 40 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CRL has an expected report date of Feb 16, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 40.2% above the $2.39 reported for the quarter ended Dec 31, 2025.
CRL Earnings Call
The latest CRL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Revenue for the quarter ended Sep 30, 2026 was $982.73M, down 1.7% from $1.00B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.09 | $2.98 | $2.93 - $3.09 | +3.69% | Beat | +27.2% | 13 | 6 up, 1 down | Nov 4, 2026 | $982.73M |
| Jun 30, 2026 | $3.02 | $2.72 | $2.58 - $2.91 | +11.03% | Beat | -3.2% | 12 | N/A | Aug 5, 2026 | $1.00B |
| Mar 31, 2026 | $2.06 | $1.95 | $1.91 - $2.11 | +5.64% | Beat | -12.0% | 13 | 2 up, 4 down | May 7, 2026 | $995.83M |
| Dec 31, 2025 | $2.39 | $2.33 | $2.25 - $2.44 | +2.58% | Beat | -10.2% | 14 | 2 up, 1 down | Feb 18, 2026 | $994.23M |
| Sep 30, 2025 | $2.43 | $2.32 | $2.30 - $2.48 | +4.74% | Beat | -6.2% | 14 | 1 up, 1 down | Nov 5, 2025 | $1.00B |
| Jun 30, 2025 | $3.12 | $2.55 | $2.46 - $2.57 | +22.35% | Beat | +11.4% | 14 | 3 up, 0 down | Aug 6, 2025 | $1.03B |
| Mar 31, 2025 | $2.34 | $2.07 | $2.00 - $2.27 | +13.04% | Beat | +3.1% | 15 | 3 up, 6 down | May 7, 2025 | $984.17M |
| Dec 31, 2024 | $2.66 | $2.53 | $2.45 - $2.64 | +5.14% | Beat | +8.1% | 16 | 0 up, 5 down | Feb 19, 2025 | $1.00B |
| Sep 30, 2024 | $2.59 | $2.42 | $2.36 - $2.49 | +7.02% | Beat | -4.8% | 15 | 3 up, 0 down | Nov 6, 2024 | $1.01B |
| Jun 30, 2024 | $2.80 | $2.39 | $2.36 - $2.43 | +17.15% | Beat | +4.1% | 16 | 1 up, 0 down | Aug 7, 2024 | $1.03B |
| Mar 31, 2024 | $2.27 | $2.06 | $2.00 - $2.11 | +10.19% | Beat | -18.3% | 13 | 0 up, 0 down | May 9, 2024 | $1.01B |
| Dec 31, 2023 | $2.46 | $2.40 | $2.25 - $2.48 | +2.50% | Beat | -17.4% | 13 | 0 up, 0 down | Feb 14, 2024 | $1.01B |
| Sep 30, 2023 | $2.72 | $2.37 | $2.33 - $2.51 | +14.77% | Beat | +3.4% | 14 | 2 up, 0 down | Nov 8, 2023 | $1.03B |
| Jun 30, 2023 | $2.69 | $2.64 | $2.61 - $2.66 | +1.89% | Beat | -2.9% | 13 | 1 up, 0 down | Aug 9, 2023 | $1.06B |
| Mar 31, 2023 | $2.78 | $2.59 | $2.53 - $2.62 | +7.34% | Beat | +1.1% | 14 | 0 up, 0 down | May 11, 2023 | $1.03B |
| Dec 31, 2022 | $2.98 | $2.75 | $2.68 - $2.79 | +8.36% | Beat | +19.7% | 14 | 0 up, 0 down | Feb 22, 2023 | $1.10B |
| Sep 30, 2022 | $2.63 | $2.50 | $2.39 - $2.64 | +5.20% | Beat | -2.6% | 13 | 4 up, 0 down | Nov 2, 2022 | $989.16M |
| Jun 30, 2022 | $2.77 | $2.74 | $2.68 - $2.81 | +1.09% | Beat | +6.1% | 13 | 2 up, 1 down | Aug 3, 2022 | $973.13M |
| Mar 31, 2022 | $2.75 | $2.72 | $2.68 - $2.76 | +1.10% | Beat | +8.7% | 12 | 2 up, 1 down | May 4, 2022 | $913.93M |
| Dec 31, 2021 | $2.49 | $2.43 | $2.39 - $2.47 | +2.47% | Beat | +4.2% | 12 | N/A | Feb 16, 2022 | $905.05M |
| Sep 30, 2021 | $2.70 | $2.58 | $2.46 - $2.65 | +4.65% | Beat | +15.9% | 11 | N/A | Nov 3, 2021 | $895.94M |
| Jun 30, 2021 | $2.61 | $2.38 | $2.03 - $2.49 | +9.66% | Beat | +65.2% | 13 | N/A | Aug 4, 2021 | $914.61M |
| Mar 31, 2021 | $2.53 | $2.19 | $2.06 - $2.33 | +15.53% | Beat | +37.5% | 14 | N/A | May 4, 2021 | $824.57M |
| Dec 31, 2020 | $2.39 | $2.11 | $2.04 - $2.30 | +13.27% | Beat | +18.9% | 16 | N/A | Feb 17, 2021 | $790.99M |
| Sep 30, 2020 | $2.33 | $1.80 | $1.66 - $1.86 | +29.44% | Beat | +37.9% | 15 | N/A | Oct 29, 2020 | $743.30M |
| Jun 30, 2020 | $1.58 | $1.28 | $1.21 - $1.40 | +23.44% | Beat | -3.1% | 16 | N/A | Aug 5, 2020 | $682.58M |
| Mar 31, 2020 | $1.84 | $1.46 | $1.39 - $1.57 | +26.03% | Beat | +31.4% | 12 | N/A | May 7, 2020 | $707.06M |
| Dec 31, 2019 | $2.01 | $1.83 | $1.82 - $1.87 | +9.84% | Beat | +34.9% | 15 | N/A | Feb 11, 2020 | $691.14M |
| Sep 30, 2019 | $1.69 | $1.64 | $1.59 - $1.71 | +3.05% | Beat | +10.5% | 12 | N/A | Nov 6, 2019 | $667.95M |
| Jun 30, 2019 | $1.63 | $1.55 | $1.52 - $1.60 | +5.16% | Beat | +0.6% | 13 | N/A | Jul 31, 2019 | $657.57M |
| Mar 31, 2019 | $1.40 | $1.39 | $1.32 - $1.44 | +0.72% | Beat | +1.4% | 13 | N/A | May 7, 2019 | $604.57M |
| Dec 31, 2018 | $1.49 | $1.40 | $1.37 - $1.45 | +6.43% | Beat | +6.4% | 16 | N/A | Feb 13, 2019 | $601.53M |
| Sep 30, 2018 | $1.53 | $1.38 | $1.36 - $1.40 | +10.87% | Beat | +17.7% | 16 | N/A | Nov 7, 2018 | $585.29M |
| Jun 30, 2018 | $1.62 | $1.46 | $1.44 - $1.51 | +10.96% | Beat | +25.6% | 15 | N/A | Aug 8, 2018 | $585.30M |
| Mar 31, 2018 | $1.38 | $1.26 | $1.23 - $1.34 | +9.52% | Beat | +7.0% | 14 | N/A | May 10, 2018 | $493.97M |
| Dec 31, 2017 | $1.40 | $1.25 | $1.20 - $1.28 | +12.00% | Beat | +15.7% | 15 | N/A | Feb 13, 2018 | $478.48M |
| Sep 30, 2017 | $1.30 | $1.22 | $1.21 - $1.24 | +6.56% | Beat | +10.2% | 15 | N/A | Nov 9, 2017 | $464.23M |
| Jun 30, 2017 | $1.29 | $1.22 | $1.20 - $1.25 | +5.74% | Beat | +7.5% | 16 | N/A | Aug 9, 2017 | $469.13M |
| Mar 31, 2017 | $1.29 | $1.14 | N/A | +13.16% | Beat | +31.6% | N/A | N/A | May 10, 2017 | $445.76M |
| Dec 31, 2016 | $1.21 | $1.11 | N/A | +9.01% | Beat | +21.0% | N/A | N/A | Feb 14, 2017 | $466.79M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $10.28, within 4 cents of the year before. It was $4.57 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $10.28 | N/A |
| Dec 31, 2024 | $10.32 | -3.1% |
| Dec 31, 2023 | $10.65 | -4.3% |
| Dec 31, 2022 | $11.13 | +7.7% |
| Dec 31, 2021 | $10.33 | +26.9% |
| Dec 31, 2020 | $8.14 | +21.0% |
| Dec 31, 2019 | $6.73 | +11.8% |
| Dec 31, 2018 | $6.02 | +14.0% |
| Dec 31, 2017 | $5.28 | +15.5% |
| Dec 31, 2016 | $4.57 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,709 | 13 | |
| 2026Q2 | Jun 30, 2026 | 10,825 | 15 | |
| 2026Q1 | Mar 31, 2026 | 8,753 | 17 | |
| 2025Q4 | Dec 31, 2025 | 10,026 | 10 | |
| 2025Q3 | Sep 30, 2025 | 8,989 | 12 | |
| 2025Q2 | Jun 30, 2025 | 8,915 | 12 | |
| 2025Q1 | Mar 31, 2025 | 8,806 | 13 | |
| 2024Q4 | Dec 31, 2024 | 9,091 | 14 |
2026Q3 Earnings Call
Opening remarks
Todd Spencer Vice President, Investor Relations Good morning, and welcome to Charles River Laboratories Third Quarter 2026 Earnings Conference Call and Webcast. This morning, I am pleased to be joined by Birgit Girshick, our Chief Executive Officer, and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the third quarter of 2026, as well as our financial guidance. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on the Investor Relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans, and prospects for the company constitute forward-looking statements under federal securities law, including the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated. During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and the reconciliations on the Investor Relations section of our website. I will now turn the call over to Birgit Girshick.
Birgit Girshick Chief Executive Officer Thank you, Todd, and good morning. We are pleased today to report another solid quarter with revenue and non-GAAP earnings per share that exceeded our prior outlook, continued momentum in the improving biopharmaceutical demand environment, and additional progress toward the execution of our Pathway to Purpose strategic vision. It was wonderful to see many of you at our Investor Day just over one month ago, and I hope that you found it to be an informative discussion about our strategic initiatives designed to enhance our operational excellence and strengthen our scientific leadership, as well as our future growth drivers and long-term financial targets. As I mentioned, our focus is to simplify the company and move faster, invest where we can win, and continue to lead as the scientific partner of choice for the critical work that our clients do. By executing on these goals, we believe it will translate into higher growth and operating margins and drive long-term shareholder value creation.
Frequently Asked Questions About CRL
When is Charles River Laboratories's next earnings date?
Charles River Laboratories's next earnings report is expected for Feb 16, 2027.
Did CRL beat earnings estimates last quarter?
Yes. Charles River Laboratories reported EPS of $3.09 for the quarter ended Sep 30, 2026, above the $2.98 estimate, a 3.69% surprise.
What EPS do analysts expect from CRL next quarter?
The consensus EPS estimate for Charles River Laboratories for the quarter ending Dec 31, 2026 is $3.35 from 15 analysts, with estimates from $3.16 to $3.56.
How often does CRL beat earnings estimates?
Charles River Laboratories beat the EPS estimate in each of the last 40 quarters, with an average surprise of +9.31%.
CRL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts